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Abstract: As part of our search for bioactive compounds from plant biodiversity, 29 with-
anolides were recently isolated from three members of the Solanaceae: Physalis longifolia,
Vassobia breviflora, and Withania somnifera. Six derivatives were prepared from these natu-
rally occurring withanolides. All compounds were evaluated for in vitro antiproliferative
activity against an array of cell lines [melanoma cell lines (B16F10, SKMEL28); human head
and neck squamous cell carcinomas (HNSCC) cell lines (JMAR, MDA1986, DR081-1);
breast cancer cell line (Hs578T), and non-malignant human cell line (MRC5)]. This led to
the discovery of 15 withanolides, with IC50 values in the range of 0.067−17.4 μM, including
withaferin A, withaferin A 4,27-diacetate, 27-O-glucopyranosylwithaferin A, withalongolide
H, withalongolide C, withalongolide A, withalongolide A 4,27-diacetate, withalongolide A
4,19,27-triacetate, withalongolide B, withalongolide B 4-acetate, withalongolide B
4,19-diacetate, withalongolide D, withalongolide E, withalongolide G, and 2,3-dihydrowith-
aferin A 3-O-sulfate. In order to update the growing literature on withanolides and their activ-
ities, we summarized the distribution, structural types, and antiproliferative activities for all
published withanolides to date. The structure–activity relationship analysis (SARA) con-
firmed the importance of the presence of a Δ2-1-oxo-functionality in ring A, a 5β,6β-epoxy
or 5α-chloro-6β-hydroxy grouping in ring B, and nine-carbon side chain with a lactone moi-
ety for cytotoxic activity. Conversely, the SARA indicated that the –OH or –OR groups at
C-4, 7, 11, 12, 14, 15, 16, 17, 18, 19, 20, 23, 24, 27, and 28 were not contributors to the
observed antiproliferative activity within the systems analyzed. 
Keywords: antiproliferative; Physalis longifolia; Solanaceae; structure classification; struc-
ture–activity relationship; Vassobia breviflora; Withania somnifera; withanolide.
INTRODUCTION
The name “withanolides” was originally given to a family of C28 ergostane-type steroidal δ-lactones
(derived from a parent 22-hydroxy-26-oic acid) isolated from the genus Withania (Solanaceae). The
term “withan” refers to Withania and “-olide” to the presence of lactone functionality in this type of
compound. With the structural elucidation of withaferin A 1 (Fig. 1) in 1965, a new area of withano-
lide chemistry was initiated [1]. Further investigations in this field led to the discovery of many hun-
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dreds of additional compounds, which include 22 related but different structural types such as: (1) new
withanolides exhibiting γ-lactone functionality (from 23-hydroxy-26-oic or 28-hydroxy-26-oic acids),
or γ-lactol functionality (from 28-hydroxy-26-als), or δ-lactol functionality (from 22-hydroxy-26-als)
in the side chain (Fig. 2); (2) new withanolides isolated from sources other than the genus Withania
(Table 1); and (3) a number of structural varieties with novel skeletons derived or modified from, or bio-
genetically related to, the highly oxygenated withanolides by ring fission, cyclization, and skeleton
rearrangements in either or both of the steroid nucleus and in the nine-carbon side chain [2–8]. In view
of these findings, the original term “withanolide” is no longer limited to its primary definition, and it
has expanded to encompass the structurally diverse variants bearing different carbon scaffolds, such as
those present in acnistin, joborol, neophysalin, nicandrenone, physalin, taccalonolide, and withajardin
(Fig. 2).
In recent years, withanolides have held the interest of the scientific community owing to their
structural features and display of significant pharmacological activities—antimicrobial, antitumor, anti-
inflammatory, immunomodulatory, and insect-antifeedant [2–4,9]. Over the last 46 years, approxi-
mately 750 withanolides, exhibiting more than 22 carbon skeletons (Fig. 2), have been reported from
various plant sources. As listed in Table 1, withanolides are predominant in 25 genera (including
Acnistus, Datura, Deprea, Discopodium, Dunalia, Iochroma, Jaborosa, Lycium, Nicandra, Physalis,
Solanum, Trechonaetes, Tubocapsicum, Vassobia, Withania, and Witheringia) of the Solanaceae family
[2–7,10–12]. Not limited to the Solanaceae, withanolides have also been isolated from a smaller num-
ber of species in the Dioscoreaceae [13], Fabaceae [7], Lamiaceae [2], Myrtaceae [14], Taccaceae [2],
and from two genera in the marine Alcyoniidae [15,16]. Although the large family Solanaceae is com-
posed of six subfamilies, with the exception of Browallia viscosa, all species containing withanolides
belong to the subfamily Solanoidea [3,4]. Within the Solanoideae Jaborosa, Physalis, and Withania
have been the genera most extensively studied to date. For example, more than 130 withanolides with
diversified functional groups were isolated from different parts (whole plant, aerial parts, flowers, fruits,
leaves, roots, and stem barks) of Withania somnifera, a traditional plant of wide use in Ayurvedic med-
icine. This plant contains the largest number of withanolides reported from any one species so far. All
the withanolides from Withania possess only a type Ia skeleton (Fig. 2), while those reported from
Physalis show greater variety with more than 10 structural types (Fig. 2 and Table 1).
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Fig. 1 Withanolide carbon-frame and structure of withaferin A 1.
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Fig. 2 Twenty-two structure types of withanolides based on their carbon skeletons (1965–2011).
(continues on next page)
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Type I withanolides (Fig. 2), also called unmodified withanolides, are the most abundant form
found in nature. With approximately 540 compounds in this category reported to date, they are distrib-
uted in the majority of the genera listed in Table 1. From the biogenetic origin, it is likely that type I
compounds are precursors to the more advanced structural types II−XXII. Type I withanolides that dis-
play the most promising antiproliferative characteristics also contain Δ2-1-oxo-functionality in ring A,
a 5β,6β-epoxy-group in ring B, and a nine-carbon side chain incorporating the δ-lactone functionality
found in withaferin A 1 [17], withacnistin 59 [18,19], withanolide D 48 [20–23], withanolide E 36
[8,24–27], and 4β-hydroxywithanolide E 37 (Fig. 4) [8,24–27]. Withaferin A 1 (Fig. 1) was shown to
induce apoptosis in vitro and in vivo by suppressing the growth of an array of tumor cells, including
H. ZHANG et al.
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Fig. 2 (Continued).
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breast, pancreatic, prostate, lung, leukemia, as well as various head and neck squamous cell carcinomas
(HNSCCs) [17]. This compound has the potential for development as an antiproliferative agent.
As part of our continuing investigations to discover drug leads from plant biodiversity, we have
explored the antiproliferative potential of compounds present in several members of the large family
Solanaceae. An approach of in vitro MTS cytotoxicity bioassay of Physalis longifolia Nutt., Vassobia
breviflora (Sendtn.) Hunz, and Withania somnifera (L.) Dunal led to the identification of bioactive with-
anolides. A panel of HNSCC cells (JMAR, MDA1986, and DR081-1), melanoma cells (B16F10 and
© 2012, IUPAC Pure Appl. Chem., Vol. 84, No. 6, pp. 1353–1367, 2012
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Table 1 Sources of withanolides and their corresponding structure types.
Family Species Structure type
Solanaceae 1 Acnistus arborescens, A. australis, A. breviflorus, A. lorentzii, I, XIV
A. ramiflorus
2 Aureliana fasciculata [10] I
3 Brachistus stramoniifolius I
4 Browallia viscosa I, VI
5 Datura fastuosa, D. ferox, D. innoxia, D. metel, D. quercifolia, I, III
D. stramonium, D. tatula
6 Deprea orinocensis, D. subtriflora I, IX, XV
7 Discopodium pernninervivum I, XIV
8 Dunalia arborescens, D. australis, D. brachyacantha, D. solanacea, I, XIV
D. tubulosa
9 Exodeconus maritimus I
10 Hyoscyamus niger, H. muticus I
11 Iochroma australe , I. coccineum, I. fuchsiodies, I. gesnerioides I
12 Jaborosa araucana, J. bergii, J. caulescens, J. integrifolia, I, IV, VIII, XIII, XVI
J. kurtzii, J. laciniata, J. lanigera, J. leucotricha, J. magellanica,
J. odonelliana, J. parviflora, J. rotacea, J. runcinata, J. sativa
13 Larnax glabra [11] I
14 Lycium chinense, L. halimifolium I
15 Mandragora officinarum [12] I, XIV
16 Nicandra physaloides I, VI
17 Physalis alkekengi, P. angulata, P. chenopodifolia, P. cinerascens, I, III, V, VIII, XI,
P. coztomatl, P. curasavica, P. divaricata, P. franchetii, XVII, XIX, XX,
P. ixocarpa, P. lanceifolia, P. longifolia, P. minima, P. peruviana, XXI, XXII
P. philadelphica, P. pubescens, P. solanaceus, P. virginiana,
P. viscosa
18 Salpichroa origanifolia I, VI
19 Saracha viscosa XIX
20 Solanum ciliatum, S. sisymbrifolium I, II
21 Trechonaetes laciniata I
22 Tubocapsicum anomalum I, VII, XIV, XV
23 Vassobia lorentzii, V. breviflora I
24 Withania adpressa, W. aristata, W. coagulans, W. frutescens, I
W. obtusifolia, W. somnifera
25 Witheringia coccoloboides, W. hunzikeri, W. solanacea XIX
Dioscoreaceae Dioscorea japonica [13] I
Fabaceae Cassia siamea I
Lamiaceae Ajuga parviflora, A. bracteosa I
Myrtaceae Eucalyptus globulus [14] I
Taccaceae Tacca chantrieri, T. integrifolia, T. paxiana, T. plantaginea, I, XVIII
T. subflabellata 
Alcyoniidae Paraminabea acronocephala, Minabea sp. (soft coral) [15,16] I
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Fig. 3 Withanolides (1, 3–6, 9, 12–18, and 20–35) from Physalis longifolia, Vassobia breviflora, and Withania
somnifera and their derivatives (2, 7, 8, 10, 11, and 19) [17,28,29].
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SKMEL28), and/or, human breast cancer cell lines (Hs578T) and non-malignant human renal epithe-
lial cell line (MRC5) were used to evaluate the extracts/fractions/compounds. This work resulted in the
isolation and characterization of 35 withanolides (1–35, Fig. 3). Of these, 29 withanolides (1, 3–6, 9,
12–18, and 20–35) were isolated from the three taxa investigated whereas the remaining six analogues
(2, 7, 8, 10, 11, and 19) were prepared from the naturally occurring compounds (1, 6, and 9). In this
report, we provide a summary of the withanolide chemistry and anti proliferative results obtained dur-
ing our studies [17,28,29] and attempt to provide a structure–activity relationship analysis (SARA) in
comparison with published data in the literature for other withanolides with antiproliferative activity. 
RESULTS AND DISCUSSION
Our own investigation of selected members of the Solanaceae afforded withanolides 1, 20, and 22 from
the aerial parts of Vassobia breviflora [17], withanolides 1, 14, 17, 18, and 24–30 from the leaves of
Withania somnifera [28], as well as withanolides 1, 3–6, 9, 12, 13, 15–18, 20–23, and 31–35 from the
aerial part of Physalis longifolia [29]. The acetate derivatives 7 and 8 were prepared from withalon-
golide A 6; compounds 10 and 11 were obtained from withalongolide B 9 while compounds 2 and 19
were derived from withaferin A 1. Withanolides 13–17 are likely to be artifacts formed during the iso-
lation process. The structures of 1–35 were determined by electrospray ionization-mass spectrometry
(ESI-MS) and 2D NMR experiments while those of 5, 6, 9, 13, 19, and 28 [28,29] were confirmed by
X-ray crystallographic analysis.
Based on their carbon skeletons, the withanolides isolated by our group can be assigned to four
structural types with various degrees of oxygenation: type I (1–12, and 15–30), type VIII (31–35), type
XI (13), and type XII (14). All the compounds show the commonly oxygenated carbons at C-1, 22, and
26 except compound 35 which lacks an oxygenated C-1. Further oxygenated positions can occur at C-3
(12, 15–17, 20–25, 31, and 33–35), C-4 (1–12, 15–22, and 28–30), C-5 and C-6 in the form of an epoxy-
group (1–11 and 15–22), C-6 and C-7 in the form of an epoxy-group (26 and 27), C-11 (5 and 15), C-17
(26 and 28), C-19 (6, 9, 16, 21, 23, and 31), C-20 (27), C-27 (1–8, 12–18, and 20–30), and C-28
(31–35). In addition, withanolides 21 and 22 occur as 3-O-sulfates, while withanolides 3, 4, 23–25, and
31–35 occur as withanolide saponins with one or two sugar residues and withanolides 28 and 29 are
chlorinated at C-6. 
All 35 withanolides isolated during our studies were tested against the HNSCC cells (JMAR,
MDA1986, and DR081-1), melanoma cells (B16F10 and SKMEL28), and/or breast cancer cells
(Hs578T) as well as non-malignant human renal epithelial cells (MRC5) for their in vitro antiprolifer-
ative activities. Cisplatin was used as a positive control. The results, expressed as IC50 (50 % inhibition
of cell growth), are summarized in Table 2. Overall, 15 withanolides (1–11, 16–17, and 21–22) includ-
ing the five acetate derivatives (2, 7, 8, 10, and 11) showed antiproliferative effects against the cells
tested with IC50 values in the range 0.067−17.4 μM, while the other withanolides were inactive when
tested at the higher concentration of 20 μM. A preliminary structure–activity relationship (SAR) could
be inferred based on the assay data obtained.
© 2012, IUPAC Pure Appl. Chem., Vol. 84, No. 6, pp. 1353–1367, 2012
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Table 2 IC50 values (μM) of withanolides (natural and derivatives) against six cell lines [17,29].
Withanolide Description B16F10 SKMEL28 JMAR MDA1986 DR081-1 MRC5 Hs578T
1 Withaferin A 0.29 3.96 2.0 0.80 1.09 0.20 1.19
2 Withaferin A 4,27-diacetate 0.15 0.11 0.19 0.32 0.76 – –
3 27-O-Glucopyranosylwithaferin A 3.65 8.3 4.20 NA NA 5.24 8.79
4 4'-O-Rhamnosyl 3 NA 17.4 8.24 8.1 NA 8.72 11.08
5 11β-Hydroxywithaferin A 0.49 2.99 0.77 2.64 5.46 3.60 2.47
6 19-Hydroxywithaferin A 11.1 5.06 5.32 3.34 2.37 12.7 2.22
7 6 4,27-Diacetate 0.098 0.81 0.14 2.24 1.28 0.41 0.46
8 6 4,19,27-Triacetate 0.067 0.54 0.16 0.91 0.29 0.58 0.32
9 27-Deoxy-6 0.2 3.91 0.17 1.3 0.90 0.40 0.47
10 9 4-Acetate 0.19 0.64 0.12 0.49 0.96 0.16 0.43
11 9 4,19-Diacetate 0.13 0.27 0.24 0.11 0.54 0.51 0.26
16 2,3-Dihydro-3-methoxy-6 3.21 9.27 4.69 NA 5.84 6.5 8.43
17 2,3-Dihydro-3-methoxy-5 5.57 11.6 12.0 8.34 NA 7.33 –
21 2,3-Dihydro-6 3-O-sulfate 1.33 4.8 2.25 2.02 NA 3.33 3.4
22 2,3-Dihydrowithaferin A 0.18 5.12 0.48 0.27 2.46 1.35 1.16
3-O-sulfate
Cisplatin Positive control 1.0 1.07 1.12 1.62 – 8.90 –
Note: Cell lines include melanoma cell lines (murine B16F10 and human SKMEL28), HNSCC cell lines (JMAR, MDA1986,
and DR081-1), non-malignant human renal epithelial cell line (MRC5), and breast cancer cell line (Hs578T); – not tested; NA:
no activity, meaning IC50 > 20 μM.
Direct comparison revealed that opening of the 5β,6β-epoxy-group of withaferin A 1 to furnish
the corresponding 5β,6α-diol 29 or 6α-chloro-5β-ol 30 resulted in loss of activity. These findings con-
firm that the 5β,6β-epoxy-group in ring B is essential for the observed cytotoxic activity, in agreement
with results previously reported in the literature for compounds with similar structural features [25–27].
Withanolides 15–22 contain a 5β,6β-epoxy-group in ring B but lack a Δ2-1-oxo-system in ring A.
A loss of activity was observed when this latter feature is absent, by comparing activity of withaferin
A 1 with 2,3-dihydrowithaferin A 18 or 2,3-dihydro-27-deoxywithaferin A 19, or 2,3-dihydro-3β-
hydroxywithaferin A 20. A decrease of activity was also observed when Δ2-1-oxo-functionality was
replaced with a 2,3-dihydro-3β-methoxy moiety, by comparing withaferin A 1 with 2,3-dihydro-3β-
methoxywithaferin A 17, and withalongolide B 5 with 2,3-dihydro-3β-methoxywithalongolide C 15.
On the other hand, the activity observed for 2,3-dihydrowithalongolide A 3β-O-sulfate 21 and
2,3-dihydrowithaferin A 3β-O-sulfate 22 was likely due to their spontaneous conversion in the cell cul-
ture media to the corresponding withalongolide A 6 and withaferin A 1, both compounds having
Δ2-1-oxo-functionality [30]. Our data thus confirm the significance of the presence of this ring A fea-
ture for the observed cytotoxic activity and are in agreement with results available in the literature
[24,26].
As in the case of withaferin A 1, withanolides 2–11 with identical functionality in rings A and B
were also active, further supporting the significance of this functional array. In contrast, withanolides
12–14 and 23–35, in which it is absent, were shown to be inactive.
Furthermore, withaferin A 1, 27-O-glucopyranosylwithaferin A 3, and 27-O-[α-L-rhamnopyra-
nosyl(1 → 4)]-glucopyranosylwithaferin A 4, in which the combination of 5β,6β-epoxy- and Δ2-1-oxo-
functionality is retained, showed different activities against the cells tested. Withanolide glycoside 3
with one sugar residue was less active relative to the aglycone 1, while withanolide saponin 4 with two
sugar residues displayed less cytoxicity when compared to 3. This observation suggested that glyco -
sylation of withanolides resulted in a decrease of cytotoxic activity. On the other hand, esterification of
the hydroxyl groups at C-4, C-19, and C-27 increased cytotoxicity when comparing withaferin A 1 with
withaferin A 4,27-diacetate 2; withalongolide A 6 with withalongolide A 4,27-diacetate 7 and witha-
longolide A 4,19,27-triacetate 8; withalongolide B 9 with withalongolide B 4-acetate 10 and withalon-
H. ZHANG et al.
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golide B 4,19-diacetate 11 (Table 2). These results are in agreement with previously reported SARs
[24–27,31]. It should be noted that the cytotoxic activity of withalongolide B 9 is comparable to that of
withaferin A 1, while the triacetate derivative 8 and diacetate derivative 11 are more potent than with-
aferin A 1 by exhibiting submicromolar activity with IC50 values in the range of 0.067–0.91 μM against
all the cell lines tested.
All withanolides so far discovered can be generally defined as poly-oxygenated steroids with all
their carbon atoms bearing oxygen functions except for C-8 and C-10. Scattered throughout the litera-
ture, it is apparent by qualitative measures, that the –OH or –OR groups do not contribute to the anti -
proliferative ability of the active withanolides. This characteristic has been observed with different cell
lines used in the evaluation of cytotoxicity for this type of compound. Various withanolides containing
hydroxyl groups at different positions were assembled from the literature (Fig. 4) and listed in Table 3
for a comparison of their respective cytotoxic activities. It is clear from these data that hydroxy- or ace-
toxy-groups at C-4, 7, 11, 12, 14, 15, 16, 17, 18, 19, 20, 23, 24, and 27 have no significant effect on
their cytotoxic activity. In most cases, withanolides possessing hydroxyl groups at such positions are
slightly less potent than those without this functional group. The results of the analysis based on our
own data as well as those obtained from the literature (Table 3) are summarized below, taking into con-
sideration different functional groups in the withanolide molecules:
4-OH group: The presence of a 4β-hydroxy-group is not required for the cytotoxic activity when
comparing the activity of withanolide E 36 and 4β-hydroxywithanolide E 37 [24,26,27]; 4-deoxy-7,16-
diacetoxywithanolide D 39 and 7,16-diacetoxywithanolide D 40 [32]; 4-deoxyphysagulin C 42 and
physagulin C 43 [33]; 4-deoxywithangulatin A 44 and withangulatin A 45 [33]; acnistin A 46 and
4-hydroxyacnistin E 47 [34]. In most cases, the 4-hydroxywithanolides are slightly less potent than the
corresponding 4-deoxywithanolides. 
7-OAc group: The presence of 7β-acetoxy-group had essentially no effect on the cytotoxic activ-
ity when comparing the activity of withanolides D 41 and 40 [32].
11-OH group: 11β-Hydroxywithaferin A 5 is slightly less potent than withaferin A 1 (Table 2). 
12-OH group: 12β-Hydroxywithanolide D 49 is slightly less potent than withanolide D 48 [22].
14,15-epoxy-group: 14α,15α-Epoxywithaferin A 50 is less potent than withaferin A 1 [35].
16-OH group: 16α-Hydroxyanomanolide A 52 is slightly less potent than anomanolide A 51
[36].
16-OAc group: 7β,16α-Diacetoxywithanolide D 40 is slightly less potent than 7β-acetoxywith-
anolide D 41 [32,37].
16,17-epoxy-group: 16α,17α-Epoxywithaolide D 55 is slightly less potent than withanolide D
48 [36].
17-OH group: 17α-Hydroxywithanolide D 56 is slightly less potent than withanolide D 48 [36].
18-OAc group: 18-Acetoxy-27-deoxywithaferin A 58 is comparable to withaferin A 1 [18].
19-OH group: 19-Hydroxywithaferin A 6 is less potent than withaferin A 1. 2,3-dihydro-19-
hydroxywithaferin A 3β-O-sulfate 22 is less potent than 2,3-dihydrowithaferin A 3β-O-sulfate 21.
4,27-Diacetoxy-19-hydroxywithaferin A 7 is comparable to 4,27-diacetoxywithaferin A 2 (Table 2). In
most cases, the 19-hydroxywithanolides are slightly less potent than the corresponding 19-deoxywith-
anolides.
20-OH group: 20-Hydroxytubocapsanolide F 56 is comparable to tubocapsanolide F 57 while
20-hydroxytubocapsanolide A 55 is slightly less potent than tubocapsanolide A 53 [36].
23-OH group: 23-Hydroxytubocapsanolide A 54 is slightly less potent than tubocapsanolide A
53 [36].
24-OH group: 24-Hydroxywithaphysacarpin 60 is less potent than withaphysacarpin 59 [38].
27-OH group: 27-Hydroxy withalongolide B 6 is less potent than withalongolide B 9 (Table 2).
It should be noted that although there are several 21-hydroxywithanolides (mainly isolated from
Datura [39] and Jaborosa [5]) and 28-hydroxywithanolides reported in the literature, their antiprolifer-
© 2012, IUPAC Pure Appl. Chem., Vol. 84, No. 6, pp. 1353–1367, 2012
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Fig. 4 Withanolides used for SARA in Table 3 (analysis from literature sources).
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Fig. 4 (Continued).
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ative screening data are not available in order to evaluate the significance of the presence of the –OH
or –OR groups at such positions. 
In addition, it has been reported that when the 5β,6β-epoxy moiety in ring B is replaced by
5α-chloro-6β-hydroxy-functionality, the cytotoxicity of the two withanolides was comparable and in
most cases the activity increased in the presence of the latter functional array. Several pairs of with-
anolides were compared for their activities, and similar results could be found in the literature: with-
anolide C 61 and withanolide E 36 [26]; physagulin I 62 and physagulin H 42 [38]; physagulin B 63
and 4-deoxy-withangulatin A 44 [38]; physagulin B 63 and withangulatin 45 [40]; and trechonolide A
64 and jaborosalactone 42 65 [27].
Side chain: Withaferin A 1, withanolide D 48, withanolide E 36, and 4β-hydroxywithanolide E
37 bearing a δ-lactone in the nine-carbon side chain are more cytotoxic than the synthetic analogue,
5,6β-epoxy-4β-hydroxy-5β-cholest-2-en-1-one 66 [24]. Tubocapsanolide F 57 with a δ-lactone in the
side chain was shown to be more potent than anomanolide A 67 with a type XIV skeleton [36], sug-
gesting the importance of a δ-lactone in order to retain cytotoxic potency.
Structural types: 4β,14α-Dihydroxywithanolide E 38 with an unmodified skeleton was more
potent than physalin F 68 with a type XIX skeleton and physanolide A with a type XVII framework
[25]. Withanolide E 36 was more potent than jaborosalactone 1 69 with a type XVI skeleton.
Tubocapsenolide A 70 with a δ-lactone in the side chain showed strong cytotoxicity comparable to that
of withanolide D 48 [36]. From these observations, it seems that type I withanoides with a lactone pres-
ent in the nine-carbon side chain showed the most potent cytotoxic activity among the diverse variants
discussed here. 
In summary, the SARA derived from our own study and from data obtained from the literature
confirmed that the 5β,6β-epoxy-group or 5α-chloro-6β-hydroxy-functionality in ring B, and conjugated
Δ2-1-oxo-functionality in ring A are the important requirements for the enhancement of antiprolifera-
tive activities in various cell systems. The unmodified type I withanolides showed more potent cyto-
toxicity than the other structural types analyzed to date. Based on these observations, it is suggested that
the –OH or –OR groups at C-4, 7, 11, 12, 14, 15, 16, 17, 18, 19, 20, 23, 24, and 27 are non-contribu-
tors to the antiproliferative activity. In most cases, withanolides possessing –OH or –OR groups at such
positions are slightly less potent than those lacking the –OH or –OR groups. Furthermore, glycosyla-
tion of withanolides decreased the cytotoxic effect while esterification of the hydroxyl groups reversed
the effect by increasing cytotoxicity (Fig. 5). 
© 2012, IUPAC Pure Appl. Chem., Vol. 84, No. 6, pp. 1353–1367, 2012
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Fig. 5 SARA of withanolides.
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